When the name “Dr. Sanjay Gupta” surfaced in recent news reports covering a partnership between the doctor and the publicly traded hemp CBD manufacturer Tree of Knowledge International Corp., many assumed that CNN’s famed medical correspondent had begun endorsing specific products. As the headlines gained steam, however, it became clear that the Dr. Sanjay Gupta featured in TOKI’s announcements is not the famed CNN correspondent but an entirely different person who happens to share the same name and title.
Some have suggested that TOKI purposefully misrepresented the partnership as a sort of publicity stunt to drive up the company’s stock prices. However, TOKI chairman and CEO Michael Caridi said in a phone interview with Ganjapreneur that any misrepresentations were due to misleading media reports, not the company’s press material.
Guys, you know this isn’t true. I haven’t partnered with anyone and have never endorsed any products. Perhaps you are doing good work, but you are absolutely misrepresenting my involvement. First I ever heard of this was from this tweet. Please correct. — Dr. Sanjay Gupta (@drsanjaygupta) August 14, 2018
CBD research is growing, too. Here are nine ways studies suggest CBD oil could benefit your health.
Amyotrophic lateral sclerosis (ALS) is a disease that causes nerve cells in the brain and spinal cord to deteriorate, resulting in loss of muscle control that worsens over time. It’s not yet understood exactly why ALS occurs, although it can be hereditary in some cases. There’s no known cure, and there are only two FDA-approved medications to help treat ALS symptoms.
Penguin CBD Capsules
$45 per container
CBD is often extracted from the cannabis sativa plant in oil form and mixed with an inert carrier oil like hemp seed oil for consumption. In recent years, CBD oil has skyrocketed in popularity thanks to its purported calming effects. It can now be found in a range of products from simple oil tinctures to CBD-infused potato chips.
5. Alleviate ALS Symptoms
A 2006 study found that Sativex—a CBD-based botanical drug approved in the United Kingdom in 2010—promoted statistically significant improvements in quality of sleep, pain during movement and pain at rest in patients with rheumatoid arthritis when compared to a placebo. It was the first controlled trial of Sativex as a treatment for rheumatoid arthritis, involving 58 patients. CBD was found to have a pain-relieving effect, as well as an ability to suppress disease activity.